Vitamin D Supplementation Shows 79% Improvement in Breast Cancer Chemotherapy Response
Key Insights
A randomized clinical trial of 80 women found that daily 2,000 IU vitamin D supplementation increased complete cancer remission rates to 43% compared to 24% in the placebo group during neoadjuvant chemotherapy.
The study demonstrated a 79% relative increase in full response rates, with most participants initially having vitamin D deficiency below 20 ng/mL at baseline.
Researchers emphasize the need for larger studies to confirm these findings, noting that vitamin D represents an accessible and inexpensive potential adjuvant to standard cancer treatment.
A new randomized clinical trial has demonstrated that vitamin D supplementation significantly improves chemotherapy response rates in breast cancer patients, with researchers reporting a 79% relative increase in complete remission rates compared to placebo treatment.
The study, published in Nutrition and Cancer and funded by FAPESP, followed 80 women over age 45 undergoing neoadjuvant chemotherapy at the oncology outpatient clinic of Hospital das Clínicas (search) at FMB-UNESP (search) in São Paulo, Brazil. Participants were randomly divided into two equal groups, with one receiving 2,000 IU of vitamin D daily while the other received placebo tablets.
Significant Improvement in Treatment Outcomes
After six months of treatment, the results showed a marked difference between the groups. Among women taking vitamin D supplementation, 43% experienced complete disappearance of their cancer following chemotherapy, compared to only 24% in the placebo group.
"Even with a small sample of participants, it was possible to observe a significant difference in the response to chemotherapy," said Eduardo Carvalho-Pessoa, president of the São Paulo Regional Brazilian Society of Mastology (search) and one of the study's authors. "In addition, the dosage used in the research [2,000 IU per day] is far below the target dose for correcting vitamin D deficiency, which is usually 50,000 IU per week."
Baseline Deficiency and Treatment Response
At the study's onset, most participants had low vitamin D levels, defined as less than 20 nanograms per milliliter (ng/mL) of blood. The Brazilian Society of Rheumatology (search) recommends maintaining levels between 40 and 70 ng/mL for optimal health.
"With supplementation, levels increased throughout chemotherapy treatment, which reinforces a possible contribution to the patients' recovery," Carvalho-Pessoa told Agência FAPESP. He noted that vitamin D represents "an accessible and inexpensive option compared to other drugs used to improve the response to chemotherapy, some of which are not even included in the list of the Unified Health System (search)."
Broader Research Context
The findings contribute to growing evidence suggesting vitamin D may function as a "chemosensitizer" that enhances cancer treatment effectiveness. A 2024 meta-analysis found that adequate vitamin D levels were associated with a 22% reduction in non-response to chemotherapy and a 35% reduction in disease progression risk across multiple cancer studies.
Additionally, a prospective cohort study published in March 2026 revealed that breast cancer patients with sufficient vitamin D had better survival and cardiovascular outcomes, with 38% of women diagnosed with invasive breast cancer showing deficiency at diagnosis.
Clinical Implications and Safety Considerations
Current guidelines recommend 600 IU of vitamin D per day for most adults and 800 IU for older individuals, with the NIH setting a safe upper limit of 4,000 IU daily for adults. The 2,000 IU dose used in this trial falls well within established safety parameters while demonstrating therapeutic benefit.
Vitamin D is primarily produced through sunlight exposure and can be obtained through certain foods. The vitamin plays crucial roles beyond bone health, including immune function and helping the body defend against infections and diseases, including cancer.
Future Research Directions
While the results are promising, researchers emphasize the need for larger studies to validate these findings. "These are encouraging results that justify a new round of studies with a larger number of participants," Carvalho-Pessoa concluded. "This will allow a greater understanding of the role of vitamin D in increasing the response to chemotherapy treatment and, consequently, in the greater likelihood of breast cancer remission."
The study's limitations include its small sample size of 80 participants, though the researchers note that even with this constraint, significant differences in treatment response were observable. Larger clinical trials will be necessary to confirm the supplement's effectiveness and clarify the mechanisms by which vitamin D influences chemotherapy response in breast cancer treatment.